6 results match your criteria: "Chris O'Brien Lifehouse and Royal Prince Alfred Hospital[Affiliation]"
Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma.
J Immunother Cancer
June 2020
Center for Immuno-Oncology, University Hospital of Siena, Instituto Toscano Tumori, Siena, Italy.
Background: We have previously reported significantly longer overall survival (OS) with ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with advanced melanoma, with higher incidences of adverse events (AEs) at 10 mg/kg. This follow-up analysis reports a 5-year update of OS and safety.
Methods: This randomized, multicenter, double-blind, phase III trial included patients with untreated or previously treated unresectable stage III or IV melanoma.
Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial.
Lancet Oncol
May 2017
University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy.
Background: A phase 2 trial suggested increased overall survival and increased incidence of treatment-related grade 3-4 adverse events with ipilimumab 10 mg/kg compared with ipilimumab 3 mg/kg in patients with advanced melanoma. We report a phase 3 trial comparing the benefit-risk profile of ipilimumab 10 mg/kg versus 3 mg/kg.
Methods: This randomised, double-blind, multicentre, phase 3 trial was done in 87 centres in 21 countries worldwide.
Predictors of early discharge after open gynecological surgery in the setting of an enhanced recovery after surgery protocol.
J Obstet Gynaecol Res
October 2016
Lifehouse Gynaecological Oncology Group, Chris O'Brien Lifehouse and Royal Prince Alfred Hospital, Sydney, Australia.
Article Synopsis
- The study aimed to identify patient characteristics that are linked to successful early hospital discharge (by postoperative day 3) in those undergoing open gynecological surgery within an ERAS protocol.
- A retrospective review of 454 patients revealed that 73.8% were discharged within 3 days, with factors like absence of malignancy, no ICU admission, and fewer complications associated with early discharge.
- The findings suggest that advanced-stage cancer and certain surgical complications prolong hospital stays, highlighting that specific patient characteristics can predict recovery outcomes.
Multifocal low-grade central osteosarcoma: a rare case.
Skeletal Radiol
July 2016
Douglass Hanly Moir Pathology, 14 Giffnock Avenue, Macquarie Park, NSW, 2113, USA.
Low-grade central osteosarcoma (LGCOS) is a rare variant of osteosarcoma. We present a rare case of multifocal LGCOS located in two distinct skeletal sites, initially noted as incidental findings on imaging for distant traumatic pathology. Both sites seemed small and innocuous on initial imaging, and were quiescent clinically, illustrating the value of close interval multimodal surveillance scanning.
View Article and Find Full Text PDFPD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma.
Lung Cancer
August 2015
Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Camperdown, NSW, Australia; Sydney Medical School, University of Sydney, Sydney, NSW, Australia; Melanoma Institute Australia, Sydney, NSW, Australia.
Objectives: Immune checkpoint blockade using inhibitors of programmed death-1 have shown promise in early phase clinical trials in NSCLC and programmed death-ligand 1 (PD-L1) tumoral expression could potentially be a useful predictive marker. Data reporting the prevalence of PD-L1 expression in NSCLC and clinicopathologic associations is very limited. We sought to determine the frequency of PD-L1 expression in NSCLC and investigate associations with clinicopathologic features and patient outcome.
View Article and Find Full Text PDFEquivocal ALK fluorescence in-situ hybridization (FISH) cases may benefit from ancillary ALK FISH probe testing.
Histopathology
November 2015
Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Camperdown, NSW, Australia.
Aims: Accurate assessment of anaplastic lymphoma kinase (ALK) gene rearrangement in non-small-cell lung cancers (NSCLCs) is critical to identify patients who are likely to respond to crizotinib. The aim of this study was to evaluate the ALK/EML4 TriCheck FISH probe in a series of NSCLCs enriched for tumours with equivocal ALK status.
Methods And Results: ALK FISH was prospectively performed on 45 NSCLCs with the ALK/EML4 TriCheck probe (ZytoVision) and the Vysis ALK break-apart probe (Abbott Molecular).